Skip to main content
Top
Published in: Respiratory Research 1/2009

Open Access 01-12-2009 | Research

Tuberculosis treatment adherence and fatality in Spain

Authors: Joan A Caylà, Teresa Rodrigo, Juan Ruiz-Manzano, José A Caminero, Rafael Vidal, José M García, Rafael Blanquer, Martí Casals, the Working Group on Completion of Tuberculosis Treatment in Spain (Study ECUTTE)

Published in: Respiratory Research | Issue 1/2009

Login to get access

Abstract

Background

The adherence to long tuberculosis (TB) treatment is a key factor in TB control programs. Always some patients abandon the treatment or die. The objective of this study is to identify factors associated with defaulting from or dying during antituberculosis treatment.

Methods

Prospective study of a large cohort of TB cases diagnosed during 2006-2007 by 61 members of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Predictive factors of completion outcome (cured plus completed treatment vs. defaulters plus lost to follow-up) and fatality (died vs. the rest of patients) were based on logistic regression, calculating odds ratios (OR) and 95% confidence intervals (CI).

Results

Of the 1490 patients included, 29.7% were foreign-born. The treatment outcomes were: cured 792 (53.2%), completed treatment 540 (36.2%), failure 2 (0.1%), transfer-out 33 (2.2%), default 27 (1.8%), death 27 (1.8%), lost to follow-up 65 (4.4%), other 4 (0.3%). Completion outcome reached 93.5% and poor adherence was associated with: being an immigrant (OR = 2.03; CI:1.06-3.88), living alone (OR = 2.35; CI:1.05-5.26), residents of confined institutions (OR = 4.79; CI:1.74-13.14), previous treatment (OR = 2.93; CI:1.44-5.98), being an injecting drug user (IDU) (OR = 9.51; CI:2.70-33.47) and treatment comprehension difficulties (OR = 2.93; CI:1.44-5.98). Case fatality was 1.8% and it was associated with the following variables: age 50 or over (OR = 10.88; CI:1.12-105.01), retired (OR = 12.26;CI:1.74-86.04), HIV-infected (OR = 9.93; CI:1.48-66.34), comprehension difficulties (OR = 4.07; CI:1.24-13.29), IDU (OR = 23.59; CI:2.46-225.99) and Directly Observed Therapy (DOT) (OR = 3.54; CI:1.07-11.77).

Conclusion

Immigrants, those living alone, residents of confined institutions, patients treated previously, those with treatment comprehension difficulties, and IDU patients have poor adherence and should be targeted for DOT. To reduce fatality rates, stricter monitoring is required for patients who are retired, HIV-infected, IDU, and those with treatment comprehension difficulties.
Literature
1.
go back to reference TB: A Global Emergency WHO Report on the TB Epidemic. Geneva: WHO/TB/94.177; TB: A Global Emergency WHO Report on the TB Epidemic. Geneva: WHO/TB/94.177;
3.
go back to reference Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: For the WHO Global Surveillance and Monitoring Project. Global Burden of Tuberculosis. Estimated Incidence, Prevalence, and Mortality by Country. JAMA 1999, 282:677–686.CrossRefPubMed Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: For the WHO Global Surveillance and Monitoring Project. Global Burden of Tuberculosis. Estimated Incidence, Prevalence, and Mortality by Country. JAMA 1999, 282:677–686.CrossRefPubMed
5.
go back to reference Orcau A, Rius C, Garcia de Olalla P, Caylà JA: Programa de Prevención y Control de la TB de Barcelona. Informe 2007. Barcelona: Publicaciones de la Agència de Salut Pública de Barcelona 2008. Orcau A, Rius C, Garcia de Olalla P, Caylà JA: Programa de Prevención y Control de la TB de Barcelona. Informe 2007. Barcelona: Publicaciones de la Agència de Salut Pública de Barcelona 2008.
6.
go back to reference Caylà JA, Caminero JA, Rey R, Lara N, Vallés X, Galdós-Tangüis H, Working Group on Completion of Tuberculosis Treatment in Spain: Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis 2004, 8:458–64.PubMed Caylà JA, Caminero JA, Rey R, Lara N, Vallés X, Galdós-Tangüis H, Working Group on Completion of Tuberculosis Treatment in Spain: Current status of treatment completion and fatality among tuberculosis patients in Spain. Int J Tuberc Lung Dis 2004, 8:458–64.PubMed
7.
go back to reference Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R: Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organisation (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998, 12:505–10.CrossRefPubMed Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R: Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organisation (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998, 12:505–10.CrossRefPubMed
8.
go back to reference Antoine D, French CE, Jones J, Watson JM: Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001. J Epidemiol Community Health 2007, 61:302–7.CrossRefPubMedPubMedCentral Antoine D, French CE, Jones J, Watson JM: Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001. J Epidemiol Community Health 2007, 61:302–7.CrossRefPubMedPubMedCentral
9.
go back to reference Rodrigo T, Caylà JA, Galdós-Tangüis H, García de Olalla P, Brugal MT, Jansà JM: Proposing indicators for evaluation of tuberculosis control programmes in large cities based on the experience of Barcelona. Int J Tuberc Lung Dis 2001, 5:432–40.PubMed Rodrigo T, Caylà JA, Galdós-Tangüis H, García de Olalla P, Brugal MT, Jansà JM: Proposing indicators for evaluation of tuberculosis control programmes in large cities based on the experience of Barcelona. Int J Tuberc Lung Dis 2001, 5:432–40.PubMed
10.
go back to reference Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG: Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999, 3:273–80.PubMed Bloch AB, Cauthen GM, Simone PM, Kelly GD, Dansbury KG, Castro KG: Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis 1999, 3:273–80.PubMed
11.
go back to reference Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL: Tuberculosis treatment outcomes. Am J Respir Crit Care Med 2004, 170:561–66.CrossRefPubMed Jasmer RM, Seaman CB, Gonzalez LC, Kawamura LM, Osmond DH, Daley CL: Tuberculosis treatment outcomes. Am J Respir Crit Care Med 2004, 170:561–66.CrossRefPubMed
12.
go back to reference Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G: Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005, 7:5–14. Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G: Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005, 7:5–14.
13.
go back to reference Falzon D, Le Strat Y, Belghiti F, Infuso A, EuroTB Correspondents: Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tubec Lung Dis 2005, 9:1224–29. Falzon D, Le Strat Y, Belghiti F, Infuso A, EuroTB Correspondents: Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tubec Lung Dis 2005, 9:1224–29.
14.
go back to reference Kliiman K, Altraja A: Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009, 33:1085–94.CrossRefPubMed Kliiman K, Altraja A: Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009, 33:1085–94.CrossRefPubMed
15.
go back to reference Duarte EC, Bierrenbach AL, Barbosa da Silva J Jr, Tauil PL, de Fátima Duarte E: Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health 2009, 63:233–238.CrossRefPubMed Duarte EC, Bierrenbach AL, Barbosa da Silva J Jr, Tauil PL, de Fátima Duarte E: Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health 2009, 63:233–238.CrossRefPubMed
16.
go back to reference Lefebvre N, Falzon D: Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J 2008, 31:1256–60.CrossRefPubMed Lefebvre N, Falzon D: Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J 2008, 31:1256–60.CrossRefPubMed
17.
go back to reference Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE: Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002, 34:752–9.CrossRefPubMed Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE: Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002, 34:752–9.CrossRefPubMed
18.
go back to reference Bustamante-Montes LP, Escobar-Mesa A, Borja-Aburto VH, Gómez-Muñoz A, Becerra-Posada F: Predictors of death from pulmonary tuberculosis: the case of Veracruz, Mexico. Int J Tuberc Lung Dis 2000, 4:208–15.PubMed Bustamante-Montes LP, Escobar-Mesa A, Borja-Aburto VH, Gómez-Muñoz A, Becerra-Posada F: Predictors of death from pulmonary tuberculosis: the case of Veracruz, Mexico. Int J Tuberc Lung Dis 2000, 4:208–15.PubMed
20.
go back to reference Grupo de Trabajo de los Talleres 2001 y 2002 de la Unidad de Investigación de Tuberculosis de Barcelona. Prevención y control de las tuberculosis importadas Med Clín (Barc) 2003, 121:549–62. Grupo de Trabajo de los Talleres 2001 y 2002 de la Unidad de Investigación de Tuberculosis de Barcelona. Prevención y control de las tuberculosis importadas Med Clín (Barc) 2003, 121:549–62.
21.
go back to reference Martin-Casabona N, Alcaide F, Coll P, González J, Manterola JM, Salvadó M, Caylà JA: Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc) 2000, 115:493–98.CrossRef Martin-Casabona N, Alcaide F, Coll P, González J, Manterola JM, Salvadó M, Caylà JA: Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc) 2000, 115:493–98.CrossRef
22.
go back to reference Pérez del Molino Bernal ML, Túñez V, Cruz-Ferro E, Fernández-Villar A, Vázquez-Gallardo R, Díaz-Cabanela D, Anibarro L, Grupo Gale de Estudio de Resistencias de M. tuberculosis: Tuberculosis. Study of Mycobacterium tuberculosis drug reistance in the region of Galicia, Spain. Int J Tuberc Lung Dis 2005, 9:1230–35.PubMed Pérez del Molino Bernal ML, Túñez V, Cruz-Ferro E, Fernández-Villar A, Vázquez-Gallardo R, Díaz-Cabanela D, Anibarro L, Grupo Gale de Estudio de Resistencias de M. tuberculosis: Tuberculosis. Study of Mycobacterium tuberculosis drug reistance in the region of Galicia, Spain. Int J Tuberc Lung Dis 2005, 9:1230–35.PubMed
23.
go back to reference Ruiz-Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Domínguez JA, García JM, Vidal R, Spanish Society of Pulmonology and Thoracic Surgery: Diagnosis and treatment of Tuberculosis. Recommendations of the Society of Pneumology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2008, 44:551–66.CrossRefPubMed Ruiz-Manzano J, Blanquer R, Calpe JL, Caminero JA, Caylà J, Domínguez JA, García JM, Vidal R, Spanish Society of Pulmonology and Thoracic Surgery: Diagnosis and treatment of Tuberculosis. Recommendations of the Society of Pneumology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2008, 44:551–66.CrossRefPubMed
24.
go back to reference American Thoracic Society and Centers Disease, Control and Prevention: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003, 167:603–66.CrossRef American Thoracic Society and Centers Disease, Control and Prevention: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003, 167:603–66.CrossRef
25.
go back to reference Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom. Thorax 1998, 53:536–48.CrossRef Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom. Thorax 1998, 53:536–48.CrossRef
26.
go back to reference Grupo de Estudio del Taller de 1999 de la Unidad de Investigación de Tuberculosis de Barcelona: Documento de Consenso sobre tratamientos directamente observados en tuberculosis. Med Clín (Barc) 2000, 115:749–57.CrossRef Grupo de Estudio del Taller de 1999 de la Unidad de Investigación de Tuberculosis de Barcelona: Documento de Consenso sobre tratamientos directamente observados en tuberculosis. Med Clín (Barc) 2000, 115:749–57.CrossRef
27.
go back to reference Marco A, Caylà JA, Serra M, Pedro R, Sanrama C, Guerrero R, Ribot N: Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998, 12:967–71.CrossRefPubMed Marco A, Caylà JA, Serra M, Pedro R, Sanrama C, Guerrero R, Ribot N: Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J 1998, 12:967–71.CrossRefPubMed
28.
go back to reference Ospina JE, Orcau A, Millet JP, Caylà JA, Casals M, Rius C, Sánchez F, the Barcelona Tuberculosis and Immigration Working Group: Effectiveness of Community Health Workers for the control of tuberculosis. Abstract Book, 40 th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Int J Tuberc Lung Dis 2009,13(suppl 1):S186. Ospina JE, Orcau A, Millet JP, Caylà JA, Casals M, Rius C, Sánchez F, the Barcelona Tuberculosis and Immigration Working Group: Effectiveness of Community Health Workers for the control of tuberculosis. Abstract Book, 40 th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Int J Tuberc Lung Dis 2009,13(suppl 1):S186.
Metadata
Title
Tuberculosis treatment adherence and fatality in Spain
Authors
Joan A Caylà
Teresa Rodrigo
Juan Ruiz-Manzano
José A Caminero
Rafael Vidal
José M García
Rafael Blanquer
Martí Casals
the Working Group on Completion of Tuberculosis Treatment in Spain (Study ECUTTE)
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2009
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-10-121

Other articles of this Issue 1/2009

Respiratory Research 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.